MML Investors Services LLC Has $1.79 Million Holdings in Genmab A/S (NASDAQ:GMAB)

MML Investors Services LLC increased its stake in Genmab A/S (NASDAQ:GMAB) by 5.4% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 73,261 shares of the company’s stock after purchasing an additional 3,785 shares during the quarter. MML Investors Services LLC’s holdings in Genmab A/S were worth $1,786,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Oppenheimer Asset Management Inc. boosted its holdings in shares of Genmab A/S by 26.3% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 218,078 shares of the company’s stock valued at $5,480,000 after buying an additional 45,376 shares during the last quarter. Choreo LLC bought a new stake in Genmab A/S in the 2nd quarter valued at $776,000. Renaissance Technologies LLC raised its stake in Genmab A/S by 7.6% in the 2nd quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock valued at $36,752,000 after acquiring an additional 103,859 shares during the period. Verition Fund Management LLC bought a new stake in Genmab A/S in the 3rd quarter valued at $709,000. Finally, Natixis Advisors LLC raised its stake in Genmab A/S by 29.8% in the 3rd quarter. Natixis Advisors LLC now owns 206,563 shares of the company’s stock valued at $5,036,000 after acquiring an additional 47,437 shares during the period. Institutional investors and hedge funds own 7.07% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. JPMorgan Chase & Co. restated a “neutral” rating on shares of Genmab A/S in a research note on Tuesday, August 20th. HC Wainwright restated a “buy” rating and issued a $50.00 price target on shares of Genmab A/S in a research note on Wednesday, October 16th. Morgan Stanley restated an “equal weight” rating and issued a $31.00 price target on shares of Genmab A/S in a research note on Wednesday, September 11th. BMO Capital Markets reiterated an “outperform” rating and set a $48.00 price objective (up previously from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Finally, Redburn Atlantic started coverage on Genmab A/S in a research report on Tuesday, October 8th. They set a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $45.20.

Genmab A/S Stock Performance

Shares of NASDAQ GMAB opened at $20.03 on Wednesday. Genmab A/S has a 52 week low of $19.85 and a 52 week high of $32.88. The stock has a market capitalization of $13.26 billion, a P/E ratio of 19.45, a PEG ratio of 0.67 and a beta of 0.96. The stock’s fifty day moving average is $22.01 and its 200 day moving average is $24.93.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.03). Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. The company had revenue of $816.10 million during the quarter, compared to the consensus estimate of $838.20 million. During the same quarter in the previous year, the business posted $0.47 EPS. Equities research analysts forecast that Genmab A/S will post 1.28 earnings per share for the current year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.